Rakovina's Q3 R&D expenses at $1.1-million
Executive Summary
- Rakovina Therapeutics reported a Q3 2025 net loss of $1,781,757, with cash and cash equivalents of $822,293 at period end.
- R&D expenses totaled $1,102,371, reflecting continued AI‑driven drug candidate development; G&A expenses were $539,174.
- The company disclosed multiple scientific milestones (ATR/mTOR dual inhibition, CNS penetration) and announced a non‑binding LOI for a joint venture with NanoPalm Ltd. to co‑develop AI‑discovered oncology therapies.
Key Details
- Financial Results (Q3 2025):
- Net loss: $1,781,757
- R&D expenses: $1,102,371
- G&A expenses: $539,174 (includes investor relations and exchange fees)
-
Cash & cash equivalents (Sept. 30, 2025): $822,293
-
Scientific & Corporate Milestones:
- Nov 24, 2025: Two scientific posters presented at the Society for Neuro‑Oncology annual meeting (ATR and PARP1 programs); ATR compounds confirmed as dual ATR/mTOR inhibitors with relevance to PTEN‑deficient tumors.
- Oct 27, 2025: New preclinical data presented at AACR‑NCI‑EORTC conference showing potent ATR inhibition and CNS penetration for the kt‑5000 series.
-
Nov 18, 2025: President & CSO Prof. Mads Daugaard invited to speak at the 9th Annual DDR Inhibitors Summit (Jan 2026).
-
Joint Venture Announcement (Aug 12, 2025):
- Non‑binding LOI with NanoPalm Ltd. to form a Saudi Arabia‑based JV for co‑development of AI‑discovered small‑molecule oncology therapies.
-
First target: dual PARP‑HDAC inhibitor KT‑3283, to be delivered via NanoPalm’s patterned lipid nanoparticle (pLNP) platform.
-
Other Corporate Updates:
- Sept 4, 2025: Senior management to attend H.C. Wainwright 27th Annual Global Investment Conference (Sept 8‑10, New York).
- Aug 26, 2025: Prof. Daugaard invited to speak at the 13th Tuscany Retreat on Cancer Research & Apoptosis (Aug 23‑30).
- July 28, 2025: Grant of 540,000 stock options at $0.70 per share; vesting equal instalments every six months over three years.
- July 15, 2025: Common shares now eligible for electronic clearing/settlement through the Depository Trust Company (DTC).
Notable Quotes
“Over the past several months, Rakovina Therapeutics has delivered a series of meaningful scientific and corporate milestones that underscore the strength of our AI‑enabled DDR pipeline… we are entering 2026 with significant momentum.” – Jeffrey Bacha, Executive Chairman
Materiality Assessment: Material – Negative (net loss and cash position constitute material financial information; combined with substantive R&D progress and strategic JV announcement).